The European Union remains at loggerheads with AstraZeneca Plc after the Anglo-Swedish drugmaker rejected demands that it take Covid-19 vaccine supplies from its U.K. factories to increase doses going to the bloc.
The origin of the dispute is Astra’s decision to prioritize Britain over the EU following a Belgian production glitch, in what Brussels claims to be a breach of contract. The two sides spoke Wednesday evening and held their ground, with another meeting expected.
